December 17, 2024 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
November 20, 2024 - Regulatory SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
April 23, 2024 - Regulatory Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
March 27, 2024 - Regulatory SynAct Pharma AB has successfully completed the bookbuilding procedure – directed issues provide the company with a total of up to 49.2 MSEK.
March 26, 2024 - Regulatory SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
March 25, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) brings forward the publication of the annual report.
March 10, 2024 - Regulatory SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
February 23, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.
January 28, 2024 - Regulatory The Board of Directors of SynAct Pharma AB has received a request to convene an EGM
